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Abstract
Background: Intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs)
lack stable tertiary and/or secondary structure yet fulfills key biological functions. The recent
recognition of IDPs and IDRs is leading to an entire field aimed at their systematic structural
characterization and at determination of their mechanisms of action. Bioinformatics studies showed
that IDPs and IDRs are highly abundant in different proteomes and carry out mostly regulatory
functions related to molecular recognition and signal transduction. These activities complement the
functions of structured proteins. IDPs and IDRs were shown to participate in both one-to-many
and many-to-one signaling. Alternative splicing and posttranslational modifications are frequently
used to tune the IDP functionality. Several individual IDPs were shown to be associated with human
diseases, such as cancer, cardiovascular disease, amyloidoses, diabetes, neurodegenerative diseases,
and others. This raises questions regarding the involvement of IDPs and IDRs in various diseases.
Results: IDPs and IDRs were shown to be highly abundant in proteins associated with various
human maladies. As the number of IDPs related to various diseases was found to be very large, the
concepts of the disease-related unfoldome and unfoldomics were introduced. Novel bioinformatics
tools were proposed to populate and characterize the disease-associated unfoldome. Structural
characterization of the members of the disease-related unfoldome requires specialized
experimental approaches. IDPs possess a number of unique structural and functional features that
determine their broad involvement into the pathogenesis of various diseases.
Conclusion: Proteins associated with various human diseases are enriched in intrinsic disorder.
These disease-associated IDPs and IDRs are real, abundant, diversified, vital, and dynamic. These
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proteins and regions comprise the disease-related unfoldome, which covers a significant part of the
human proteome. Profound association between intrinsic disorder and various human diseases is
determined by a set of unique structural and functional characteristics of IDPs and IDRs.
Unfoldomics of human diseases utilizes unrivaled bioinformatics and experimental techniques,
paves the road for better understanding of human diseases, their pathogenesis and molecular
mechanisms, and helps develop new strategies for the analysis of disease-related proteins.
Background
Introducing intrinsically disordered proteins
Proteins are the major components of the living cell. They
play crucial roles in the maintenance of life. Protein dys-
functions may cause development of various pathological
conditions For more than 75 years it has been believed
that the specific functionality of a given protein is prede-
termined by its unique 3-D structure [1,2]. For these struc-
tured proteins, the sequence → structure → function
paradigm has become paramount. According to this view,
a protein's function depends on its prior folding into a
unique three-dimensional structure. In such cases, the
amino acid sequence determines the protein's unique 3-D
structure.
Evidence is rapidly accumulating that many protein
regions and even entire proteins lack stable tertiary and/or
secondary structure in solution yet possess crucial biolog-
ical functions [3-25]. These naturally flexible proteins and
regions are known by different names, including intrinsi-
cally disordered [8], natively denatured [26], natively
unfolded [27], intrinsically unstructured [4], natively dis-
ordered [21], and inherently disordered [25,28,29]. In
this article, the terms "intrinsically disordered proteins"
and "intrinsically disordered regions" (IDPs and IDRs,
respectively) are used to describe such proteins and
regions generally and "natively denatured" or "intrinsi-
cally unstructured" are used for collapsed and extended
random coils that lack significant amounts of stable sec-
ondary structure (see below).
IDPs and IDRs can contain collapsed-disorder, semi-col-
lapsed disorder, or extended-disorder under physiological
conditions in vitro [6,12,19]. Collapsed-disorder consists
mainly of molten globules, which are formed by hydro-
phobic collapse, which have stable but dynamic second-
ary structure, and which have flexible and dynamic side
chains [14,30-38]. Semi-collapsed structures arise because
water is a poor solvent for the peptide backbone and
include, for example, polyglutamine regions [28], other
polar sequences [29], and pre-molten globules [14,39-
41]. Pre-molten globules may contain regions with tran-
sient secondary structure or small amounts of localized,
fairly stable secondary structure. Extended-disorder arises
from chains having repulsion arising from a net charge,
and these proteins and regions resemble the more classi-
cal idealized random coil. Because of the lack of a hydro-
phobic core and the presence of only the marginal levels
of residual secondary structure, native coils and native
pre-molten globules are grouped together in a class of
natively unfolded or intrinsically unstructured proteins
[11,12].
In contrast to the long history regarding structured pro-
teins, the study of the IDP phenomenon is emerging only
very recently (Figure 1). This transition is occurring mostly
due to the efforts of four research groups, which almost
simultaneously and completely independently came to
the important conclusion that naturally flexible proteins,
instead of being just rare exceptions, represent a new and
very broad class of proteins [1,2,4,11]. This important
conclusion was reached from different starting points
using very different experimental approaches, including:
bioinformatics (Dr. A.K. Dunker's group), NMR spectros-
copy (Dr. P.E. Wright's group), multiparametric protein
folding/misfolding studies (Dr. V.N. Uversky's group),
and protein structural characterization (Dr. P. Tompa's
group). The bioinformatics approach has played an espe-
cially crucial role in shaping this field, bringing coherence
and recognition to proteins that were previously viewed
individually as outliers from the main stream [42]. After
publication of key studies and reviews describing this new
concept, the literature on IDPs and IDRs is virtually
exploding (see Figure 1).
Figure 2 represents the modern understanding of the fate
of a polypeptide chain inside a cell and schematically
shows the three types of intrinsic disorder mentioned
above, native coil, native pre-molten globule, and native
molten globule. According to this hypothesis, newly syn-
thesized proteins can either fold to gain a unique structure
necessary for the catalytic and transport activities, can stay
substantially non-folded, or can misfold under some cir-
cumstances to form amyloid-like fibrils. Importantly,
both folded and non-folded polypeptide chains have spe-
cific biological functions. The three endpoints are further
interlinked and some changes in the environment, inter-
action with specific binding partners, or mutations may
bring subsequent structural rearrangements. As a result,
an intrinsically disordered polypeptide can partially or
completely fold or misfold and form amyloid-like fibrils,BMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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whereas ordered protein can likewise misfold and assem-
ble into a pathogenic fibrillar form (see Figure 2) [14].
Just as the amino acid sequence of an ordered protein con-
tains the information for a highly specific folding, the
amino acid sequence of an IDP codes for lack of structure
or disorder. The validity of this hypothesis is supported by
the development of various disorder predictors [29-32] all
based on well-defined biases in the IDP sequences and
amino acid compositions [3,6,7,42-45]. For example,
natively unfolded proteins were shown to be specifically
localized within a unique region of charge-hydropathy
phase space characterized by a combination of low overall
hydropathy and high net charge [6]. More specifically, in
comparison with structured proteins, IDPs and IDRs are
generally depleted in the structure-promoting residues
(including cysteine, tryptophan, tyrosine, isoleucine, phe-
nylalanine, valine, leucine, histidine, threonine, and
asparagine) and noticeably enriched in the disorder-pro-
moting residues (aspartic acid, methionine, lysine,
arginine, serine, glutamine, proline, and glutamic acid)
[5,29,33,34].
IDPs and IDRs are highly abundant in nature. This follows
from the results of disorder prediction for many whole
proteomes. The fraction of proteins with substantial
amounts of disorder is found to be proportional to the
complexity of the organisms. IDPs/IDRs are more abun-
dant in eukaryotes than in archaea and prokaryotes. Fur-
thermore, multicellular eukaryotes were shown to have
much more predicted disorder than unicellular eukaryo-
tes [5,46,47]. In general, for mammals, ~75% of their sig-
naling proteins are predicted to contain long IDRs (> 30
residues), about half of their total proteins are predicted
to contain such long IDRs, and ~25% of their proteins are
predicted to be fully disordered [25].
IDPs and IDRs carry out pivotal biological functions, par-
ticipating in recognition and in various signaling and reg-
ulatory pathways, via specific protein-protein, protein-
nucleic acid and protein-ligand interactions [22,48-50].
Sites of various post-translational modifications (PTMs)
and sites of proteolytic attack are frequently associated
with regions of intrinsic disorder [50]. The capability of
non-folding proteins and regions to interact with collec-
tions of partners is utilized in organizing complex pro-
tein-protein interaction networks. In fact, hub proteins
have been shown to have multiple interactions, either
being intrinsically disordered and serving as an anchor, or
acting as a stable globular anchor that interacts with
intrinsically disordered regions of its targets [21,51-56].
Summarizing, whole proteins or protein regions are
intrinsically disordered if they fail to fold into 3-D struc-
tures, remaining as floppy ensembles with specific biolog-
ical functions. In our view, IDPs include molten globules,
The modern understanding of the fate of a polypeptide chain  inside a cell Figure 2
The modern understanding of the fate of a polypep-
tide chain inside a cell. Three types of IDPs, native coil, 
native pre-molten globule, and native molten globule are 
schematically shown together with the structure of an 
ordered protein and an amyloid fibril. Here, newly synthe-
sized polypeptide chain can either undergo specific folding to 
gain a unique structure necessary for the catalytic and trans-
port activities, or stay substantially non-folded or misfold and 
form amyloid-like fibrils. Both folded and non-folded proteins 
have specific biological functions.
Polypeptide
Chain Non-folding
Folding
Misfolding
Increase in the number of publications dealing with the IDPs Figure 1
Increase in the number of publications dealing with 
the IDPs. Circles 1–6 correspond to some key IDP-related 
publications in the pre-bioinformatics era. They are: 1) Land-
steiner, 1936 [110]; 2) Pauling, 1940 [111]; 3) Karush, 1950 
[112]; 4) McMeekin, 1962 [113]; 5) Jirgenesons, 1966 [114]; 
6) Doolittle, 1973 [115]. Circles 1'-4' correspond to key 
research bioinformatics articles and reviews that created and 
shaped the IDP field: 1') Romero et al., 1998 [3]; 2') Wright & 
Dyson, 1999 [4]; 3') Uversky et al., 2000 [6]; 4') Tompa, 2002 
[13].
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pre-molten globules, random coils and transiently struc-
tured forms. IDPs are highly abundant and carry out
numerous vital functions. IDPs and IDRs can be predicted
by a variety of algorithms. Experimentally, they can be
identified using various biophysical techniques, including
NMR (especially 1H-15N NOEs), X-ray crystallography
(especially missing density regions), circular dichroism,
protease sensitivity, and many others [57].
IDPs in human diseases: illustrative case studies
Proteins are involved in the maintenance of all stages of
the life cycle. The fact that protein dysfunction can cause
development of various pathological conditions was
known for a very long time. Currently, a broad range of
human diseases is linked to the failure of a specific pep-
tide or protein to adopt its functional conformational
state; i.e., to protein misfolding, loss of normal function,
gain of toxic function, and/or protein aggregation.
Although each of such diseases originates from the mis-
function of a particular protein, they all are grouped
together as protein-conformation or protein-misfolding
diseases to emphasize the common molecular mecha-
nisms of their origin. Triggers for misfolding vary for dif-
ferent proteins. Some disease-related proteins have an
intrinsic propensity to form pathologic conformation(s).
For other proteins, interactions or impaired interactions
with chaperones, intracellular or extracellular matrixes,
other proteins, small molecules and other endogenous
factors can induce conformational changes and increase
propensity to misfold. Often, misfolding and misfunction
originate from point mutation(s) or result from an expo-
sure to internal or external toxins, impaired posttransla-
tional modifications (phosphorylation, advanced
glycation, deamidation, racemization, etc.), an increased
probability of degradation, impaired trafficking, lost
binding partners or oxidative damage. All these factors
can act independently, additively or synergistically.
Protein-conformation diseases can affect a single organ or
be spread through multiple tissues. For example, numer-
ous amyloidoses and various neurodegenerative disorders
originate from the conversion of specific proteins from
their soluble functional states into stable, highly ordered
amyloid fibrils, and from the deposition of these aggre-
gates in the variety of organs and tissues. Although protein
aggregation is the most visible and the best studied conse-
quence of protein misfolding, pathogenesis of many
human diseases might depend on more subtle structural
changes that lead to misfunction. Many of the proteins
associated with the various conformational diseases are
involved in recognition, regulation and cell signaling and
a great number of these proteins are IDPs. This review is
an attempt to develop an overall understanding of the
roles of IDPs in various human diseases. We will start with
a couple of illustrative examples where well-characterized
IDPs were shown to be associated with the pathogenesis
of specific diseases. We will consider here α-synuclein,
p53 and HPV proteins. Additional illustrative examples
can be found in our recent review [58]. The abundance of
intrinsic disorder in various disease-associated proteins
will be revealed using specific bioinformatics and compu-
tational tools. Then, we will attempt to answer the ques-
tion why IDPs are so frequently associated with human
diseases. The overall goal of this review is to introduce a
concept of the disease-related unfoldome and to describe
a set of bioinformatics approaches that serve as specific
unfoldomics tools.
α-Synuclein, Parkinson's Diseases and other 
synucleinpathies
α-Synuclein is one of the most intensively studied IDPs
[59-61]. This is because of its association with a group of
neurodegenerative disorders, synucleinopathies, charac-
terized by the fibrillar α-synuclein aggregates in the cyto-
plasm of selective populations of neurons and glia [62-
65] and by a chronic and progressive decline in motor,
cognitive, behavioral, and autonomic functions, with the
disease phenotype depending on the distribution of the
lesions. Some of the most common synucleinopathies are
Parkinson's disease (PD), dementia with Lewy bodies
(DLB), Alzheimer's disease (AD), Down's syndrome, mul-
tiple system atrophy (MSA), and neurodegeneration with
brain iron accumulation type 1 (NBIA1). A more com-
plete list of synucleinopathies is shown in Additional file
1.
Depending on the type of pathology, α-synuclein inclu-
sions are present in neurons (both dopaminergic and
non-dopaminargic), where they can be deposited in peri-
karya or in axonal processes of neurons, and in glia. At
least five morphologically different α-synuclein-contain-
ing inclusions have been described: Lewy bodies, Lewy
neurites (dystrophic neurites), glial cytoplasmic inclu-
sions, neuronal cytoplasmic inclusions and axonal sphe-
roids [60,61].
The protein that links various synucleinopathies is α-
synuclein, which is a typical IDP with low level of ordered
structure under the physiological conditions in vitro [59].
According to the detailed conformational studies, the
structure of α-synuclein is extremely sensitive to the envi-
ronment, and this protein is known to adopt a variety of
structurally unrelated conformations. The list includes a
natively unfolded (mostly disordered) state, an amy-
loidogenic partially folded conformation, and different α-
helical or β-structural species folded to a different degree,
both monomeric and oligomeric [59]. It might also form
aggregates with different morphology, oligomers (spheri-
cal or annular), amorphous aggregates, and amyloid-like
fibrils [59]. Finally, similar to other fibrillating proteinsBMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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[66], α-synuclein was shown to assemble into the annular
aggregates able to form ion-conducting, transmembrane
channels [67-69]. As α-synuclein has a high intrinsic pro-
pensity to aggregate, it represents a unique model for the
structural and mechanistic analysis of amyloidogenic
IDPs.
To describe the structural malleability of α-synuclein, the
concept of a protein-chameleon was proposed, according
to which the structure of α-synuclein depends on its envi-
ronment and the choice between various conformations
is determined by the peculiarities of the protein's sur-
roundings [59]. This conformational plasticity is deter-
mined by a specific folding-energy landscape of an IDP,
which in contrast to that of an ordered protein, is charac-
terized by numerous local energy minima, leading to a
highly frustrated system without any stable well-folded
conformation [58]. Such an energy landscape can explain
the conformational plasticity of an IDP and show how
such a protein can specifically interact with many ligands
of different nature and respond differently to various envi-
ronmental challenges. The interaction with a particular
binding partner (or other changes in the environment)
affects the IDP folding landscape making some energy
minima deeper and some energy barriers higher, therefore
determining the ability of such a protein to fold in a tem-
plate-dependent manner [58].
p53 and cancer
The p53 protein is a transcription factor located at the
center of a large signaling network. It regulates expression
of over 150 genes, including p21,  GADD45,  MDM2,
IGFBP3, and BAX  [70]. Some of the genes induced or
inhibited by p53 are involved in such cellular processes as
cell cycle progression, apoptosis induction, DNA repair,
response to cellular stress, among other functions [71].
When p53 function is lost, either directly through muta-
tion or indirectly through several other mechanisms, the
cell often undergoes cancerous transformation [72]. For
this reason, a loss of p53 function is considered as a major
factor in cancer development [72].
To carry out its numerous signal transduction functions,
p53 interacts physically with a large number of other pro-
teins. Many of these interactors are transcription factors,
and many more are activators or inhibitors of p53 trans-
activation activities. The p53-Mdm2 interaction is of spe-
cial interest due to its direct relation to the oncogenesis.
The Mdm2 protein inactivates p53 by binding to its tran-
scription activation domain [73]. This interaction pre-
vents p53 from activating its target genes in three ways
[74]: (i) It directly blocks p53 from binding to various
transcription factors; (ii) Mdm2 acts as a ubiquitin ligase,
targeting p53 for destruction; (iii) Mdm2 contains a
nuclear export signal, so the p53-Mdm2 complex tends to
be exported from the nucleus, thereby preventing p53
from activating genes.
Several interactions have been mapped to the N-terminal
domain (i.e., the transactivation domain), the C-terminal
domain (i.e., the regulatory domain), and the DNA bind-
ing domain (DBD) of p53 [58,71]. These domains have
also been characterized in terms of their intrinsic disorder-
order state, where the DNA binding domain is intrinsi-
cally structured and the terminal domains are intrinsically
disordered [51,58,75,76]. Additionally, many sites of var-
ious posttranslational modifications have been identified
in p53. Overall, ~70% of the interactions are mediated by
IDRs in p53 [51]. A bias toward intrinsic disorder is even
more pronounced in the sites of posttranslational modifi-
cations, with 86%, 90%, and 100% of observed acetyla-
tion, phosphorylation, and protein conjugation sites,
respectively, found in IDRs [51,58]. Clearly, p53 exten-
sively uses disordered regions to mediate and modulate
interactions with other proteins. This is illustrated by Fig-
ure 3, which represents a set of complexes of various p53
fragments or domains with numerous binding partners.
Intrinsic disorder, HPV proteins and cervical cancer
There are more than 100 different types of human papil-
lomaviruses (HPVs), which are the causative agents of
benign papillomas/warts, and cofactors in the develop-
ment of carcinomas of the genital tract, head and neck and
epidermis. With respect to their association with cancer,
HPVs are grouped into two classes, known as low- (e.g.,
HPV-6 and HPV-11) and high-risk (e.g., HPV-16 and
HPV-18) types. The entire proteome of HPV includes two
structural proteins, L1 and L2, and six nonstructural pro-
teins: E1, E2, E4, E5, E6 and E7. The last two, E6 and E7,
are known to function as oncoproteins in the high-risk
HPVs. The correlation between the amount of ID and the
ability of human papillomaviruses to cause the carcinoma
development has been recently evaluated [77]. To this
end, a detailed bioinformatics analysis of proteomes of
high-risk and low-risk HPVs with the major focus on E6
and E7 oncoproteins was performed. The results of this
analysis were consistent with the conclusion that high-risk
HPVs were characterized by the increased amount of
intrinsic disorder in transforming proteins E6 and E7 [77].
IDPs in human diseases: from individual cases to 
general picture
Although the illustrative examples given above demon-
strate the involvement of IDPs and IDRs in various dis-
eases, and despite several more cases that are scattered in
literature, all of these examples together are not sufficient
to determine the extent of IDP involvement in the patho-
genesis of human diseases. Simply put, how generally do
IDPs and IDRs play important roles in human disease? To
answer this big question, appropriate analytical tools areBMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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needed. In a fashion similar to the history of the develop-
ment of the IDP concept itself, bioinformatics is being
used to determine the extent and generality of the involve-
ment of IDPs and IDRs in human disease.
Unfoldomics of human diseases: tools to establish and 
analyze disease-related unfoldome
Unfoldome and unfoldomics
Since IDPs are highly abundant in various diseases (see
below), the "disorder in disorders" or D2 concept was
introduced to summarize work in this area [58]. As the
number of IDPs related to various diseases is very large, it
makes sense to develop the disease-related unfoldome
and unfoldomics concepts.
The use of the suffix '-ome' has a long history while '-
omics' is much more recent. The Oxford English Diction-
ary (OED) attributes 'genome' to Hans Winkler from his
1920 work [78]. While the OED suggests that 'genome'
arose as a portmanteau of 'gene' and 'chromosome', this
Disorder profile and functionality of p53 Figure 3
Disorder profile and functionality of p53. Intrinsic disorder was predicted by the PONDR® VLXT. Segments with scores 
above 0.5 correspond to disordered regions, while those below 0.5 correspond to ordered regions/binding sites. p53 is at the 
center of a large signaling network, regulating expression of genes involved in a variety of cellular processes and interacting 
with a large number of other proteins. The interaction sites are signaled by downward spikes in the plot of the predicted dis-
order. The structures of the complexes containing various p53 binding regions are displayed around the predicted disorder 
pattern. In complexes, the structures of p53 segments bound to their partners are shown in different colors. These color 
codes are also used for bars in the PONDR® VLXT plot to indicate the positions of the regions of known structure in the con-
text of the intrinsic disorder predictions. The Protein Data Bank IDs and partner names for the structures (from upper left, 
clockwise) are as follows: (1tsr DNA), (1gzh 53BP1), (1q2d gcn5), (3sak p53 (tet dom)), (1xqh set9), (1h26 cyclinA), (1ma3 sir-
tuin), (1jsp CBP bromo domain), (1dt7 s100bb), (2h1l sv40 Large T antigen), (1ycs 53BP2), (2gs0 PH), (1ycr MDM2), and (2b3g 
rpa70).BMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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does not seem to be supported by the literature. Instead,
Lederberg and McCray suggest that, as a botanist, Winkler
must have been familiar with terms such as biome (a bio-
logical community), rhizome (a root system), and phyl-
lome (the leaves covering a tree) among others, all of
which were in use well before 1920 and all of which sig-
nify the collectivity of the units involved [79]. Thus, 'ome'
implies the complete set of the objects in question, with
genome signifying the set of genes of an organism. By
changing the 'e' in '-ome' to '-ics', the new word is created
that indicates the scientific study of the '-ome' in question.
For genome, the change to 'genomics' did not occur until
1987 when a journal by this name was founded by Victor
McKusick and Frank Ruddle [79].
Many additional conversions from -ome to -omics have
subsequently occurred and a large number of "-omes"
have been accepted in biology, including but not limited
to the following: genome, proteome, interactome, metab-
olome, transcriptome, diseasome, toxicogenome, nutrige-
nome, cytome, oncoproteome, epitome, and glycome,
etc. For a more complete list, the reader is directed to
http://omics.org. Interestingly, some of the -ome words at
this website cannot be found in PubMed searches,
whereas similar words can be found. For example,
'foldome' and 'foldomics' are both listed on this website,
but a search of these words in PubMed yields no hits for
either word, while the similar word, 'foldeomics,' yields
one hit, which leads to a database containing information
about protein folding. The suffixes -ome and -omics imply
a new layer of knowledge, especially when a scientist is
dealing with the data produced by the large-scale studies,
including the high throughput experiments and the com-
putational/bioinformatics analyses of the large datasets.
The unfoldome and unfoldomics concepts are built on
the ideas given above. Unfoldomics is the field that
focuses on the unfoldome. The unfoldome is the set of
IDPs, which are also known as natively unfolded proteins,
hence the unfoldome. We are also using unfoldome to
cover segments or regions of proteins that remain
unfolded in the functional state. Unfoldomics considers
not only the identities of the set of proteins and protein
regions in the unfoldome of a given organism, but also
their functions, structures, interactions, evolution, etc.
Because IDPs and IDRs are highly abundant in nature
(~50% eukaryotic proteins are either entirely disordered
or contain long disordered regions), have amazing struc-
tural variability and possess a very wide variety of func-
tions, we thought it appropriate to name this realm of
proteins the unfoldome, with unfoldomics reflecting the
totality of the phenomena associated with IDPs and IDRs.
Computational tools for the unfoldome analysis
Obviously, when the scale of analysis increases from one
protein to many, new analytical tools are required. The set
of computational tools utilized in the bioinformatics
studies on disease-related unfoldomes is briefly intro-
duced below. This set includes compositional profiling,
disorder prediction, evaluation of the number of potential
binding sites, analysis of alternative splicing, and determi-
nation of posttranslational modifications.
Compositional profiling
A specific feature of a probable IDR is its amino-acid com-
positional bias characterized by a low content of so-called
order-promoting residues such as Cys, Trp, Phe, Tyr, Val,
Leu, and Ile, and a high content of so-called disorder-pro-
moting residues, Glu, Lys, Arg, Asp, Gln, Ser, Pro, and Thr
[7,45,80,81]. This bias can be visualized by plotting the
fractional difference in composition between a given set
of proteins and a set of ordered proteins [7,81]. These frac-
tional differences in composition between the studied set
and a set of ordered proteins are calculated for each amino
acid residue as (Cx-Corder)/Corder, where Cx is the content of
a given amino acid in the set of interest, and Corder is the
corresponding content in a set of ordered proteins. The
analysis can be performed using a web Composition Pro-
filer tool http://www.cprofiler.org/.
Disorder predictions
Predictions of the intrinsic disorder propensity can be per-
formed using a set of per-residue Predictors Of Natural
disordered regions (PONDR®) algorithms, PONDR®
VLXT, VL3 and VSL1/2 or a set of binary predictors that
predict disorder on the level of whole proteins, charge-
hydrophathy plot (CH-plot) and cumulative distribution
function (CDF) analysis. Many research groups have
developed a number of different predictors of disorder in
addition to the examples listed above. Links to many of
these predictors can be found at http://www.disprot.org.
PONDR® VLXT combines three neural networks, one for
internal sequences and one for each terminus of the
sequence. The internal predictor was trained on disor-
dered sequences from only 15 proteins whose disorder
was characterized by either X-ray or NMR studies [80]. The
terminal predictors were trained on short regions of X-ray
characterized disorder from the N- and C-terminus [82].
The merger was accomplished by performing overlapping
predictions, followed by averaging the outputs. The VLXT
training set included disordered segments of 40 or more
amino acid residues as characterized by X-ray and NMR
for the predictor of the internal regions, and segments of
five or more amino acid residues for the predictors of the
two terminal regions. VLXT most likely underestimates
the occurrence of long disordered regions in proteins.BMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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However, this algorithm is very important for finding
potential binding sites (see below).
PONDR® VL3 combines the predictions of 30 neural net-
works for the entire protein sequence and was trained
using disordered regions from more than 150 proteins
characterized by the methods mentioned above plus cir-
cular dichroism, limited proteolysis and other physical
approaches [83]. This is one of the most accurate predic-
tors of long disordered regions.
PONDR® VSL1/2 is a recently developed Various Short-
Long, version 1/2 (PONDR® VSL1/2) algorithm, which is
an ensemble of logistic regression models that predict per-
residue order-disorder [84,85]. Two models predict either
long or short disordered regions – greater or less than 30
residues – based on features similar to those used by
VLXT. The algorithm calculates a weighted average of
these predictions, where the weights are determined by a
meta-predictor that approximates the likelihood of a long
disordered region within its 61-residue window. Predictor
inputs include PSI-BLAST [86] profiles and PHD [87], and
PSI-PRED secondary structure predictions [88].
CDF analysis
Originally, cumulative distribution function (CDF) anal-
ysis summarized the per-residue disorder predictions by
plotting PONDR® VLXT scores [80,82,89] against their
cumulative frequency, which allows ordered and disor-
dered proteins to be distinguished based on the distribu-
tion of prediction scores [47]. At any given point on the
CDF curve, the ordinate gives the proportion of residues
with a PONDR® score less than or equal to the abscissa.
The optimal boundary that provided the most accurate
order-disorder classification was shown to represent seven
points located in the 12th through 18th bin [47]. Thus, for
CDF analysis, order-disorder classification is based on
whether a CDF curve is above or below a majority of
boundary points. Recently, CDF analysis was extended to
include several other per-residue predictors of intrinsic
disorder [90].
CH-plot analysis
Ordered and intrinsically unstructured proteins occupy
non-overlapping regions in the charge-hydropathy plots
(CH-plots), with natively unfolded proteins being specif-
ically localized within a particular region of charge-
hydropathy phase space, satisfying the following relation-
ship [6,47]:
where H and R are the mean hydropathy and the mean
net charge of the given protein, respectively, whereas Hb
is the "boundary" mean hydropathy value, below which a
polypeptide chain with a given R will be most probably
unfolded. The mean hydropathy, H, is defined as the
sum of the normalized hydropathy of all residues divided
by the number of residues in the polypeptide. The mean
net charge R is defined as the net charge at pH 7.0,
divided by the total number of residues [6,47].
α-MoRF predicitions
The order/disorder tendencies of IDPs as revealed by
PONDR® VLXT could be used to find disordered region(s)
involved in interaction with specific binding partners. In
fact, often IDPs have a peculiar and well-recognizable pat-
tern, where short region of predicted order is surrounded
by extended regions predicted disorder. This specific pat-
tern was used to develop a unique bioinformatics tool
dedicated to the identification of potential protein-pro-
tein interaction sites in IDPs, namely the identifier of α-
helix forming Molecular Recognition Features, α-MoRF,
which is focused on short binding regions within long
regions of disorder that are likely to form helical structure
upon binding [19,91]. The predictor utilizes a stacked
architecture, where PONDR® VLXT is used to identify short
predictions of order within long predictions of disorder
and then a second level predictor determines whether the
order prediction is likely to be a binding site based on
attributes of both the predicted ordered region and the
predicted surrounding disordered region. An α-MoRF pre-
diction indicates the presence of a relatively short (20 res-
idues), loosely structured helical region within a largely
disordered sequence [19,91]. Such regions gain function-
ality upon a disorder-to-order transition induced by bind-
ing to partner.
Alternative splicing analysis
Alternative splicing (AS) is a process responsible for the
production of multiple, mature mRNAs from a single pre-
cursor pre-mRNA by the inclusion and omission of differ-
ent segments [92]. Therefore, the AS regions are defined as
exons or parts of exons that are expressed in some, but not
in all protein sequences transcribed from a given gene. AS
is prevalent in multicellular eukaryotes [93], and it is esti-
mated that 40 – 60% of human genes yield multiple pro-
teins via this process [94]. These observations suggest that
AS provides an important mechanism for enhancing the
diversity of the proteome in multicellular eukaryotes [95].
As AS impacts many protein functions such as ligand
binding, enzymatic activity, and protein-protein interac-
tions, not surprisingly, abnormal AS has been associated
with various human diseases, including myotonic dystro-
phy [96], axoospermia [97], Alzheimer's disease [98], can-
cer [99,100] and many others.
In the disease-related unfoldome, the sequence align-
ments of genes with multiple isoforms provide informa-
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tion on the AS regions. Similarly as for a whole protein,
disorder content for an AS region is estimated as the frac-
tion of its residues that are predicted to be disordered.
PTM analysis
Posttranslational modifications (PTMs) are widely
employed by cells to modulate the functionalities of
many of their proteins. Some proteins require different
types of posttranslational modifications for their func-
tion. PTMs are classified according to the mechanisms
that are involved: addition of functional groups (e.g.,
acylation, alkylation, phosphorylation, glucosylation,
etc.); attachement of other proteins and peptides (e.g.,
ubiquitination, SUMOylation, etc.); changing of the
chemical nature of amino acids (deamidation, deimida-
tion, oxidation, etc.); and dissection of the backbone by
proteolytic cleavage. Additionally, according to the con-
formational state of the potential PTM site, PTMs can be
grouped into two major classes. The first class involves
modifications that are associated primarily with struc-
tured proteins and regions, whereas the second class com-
bines modifications that are associated primarily with
IDPs and IDRs [50]. The first class of PTMs is crucial for
providing moieties for catalytic functions, for modifying
enzyme activities or for stabilizing protein structure. This
includes formylation, protein splicing, oxidation and cov-
alent attachment of quinones and organic radicals [50].
The abundance of IDRs among the primary targets for the
second class PTMs is likely determined by the need of the
modifying enzymes to bind to their corresponding sub-
strates via high specificity/low affinity interactions; such
characteristics are typical of signaling interactions and typ-
ically involve disorder-to-order transitions of at least one
of the partners [50]. Among the second class of PTMs are
phosphorylation, acetylation, acylation, adenylylation,
ADP ribosylation, amidation, carboxylation, formylation,
glycosylation, methylation, sulfation, prenylation, ubiq-
uitination, and Ubl-conjugation (i.e., covalent attach-
ment of ubiquitin-like proteins, including SUMO, ISG15,
Nedd8, and Atg8) [50].
As amino acid compositions, sequence complexity,
hydrophobicity, charge and other sequence attributes of
regions adjacent to phosphorylation sites were found to
be very similar to those of IDPs and IDRs, a specific web-
based tool for the prediction of protein phosphorylation
sites, DISPHOS (DISorder-enhanced PHOSphorylation
predictor, http://www.ist.temple.edu/DISPHOS) was
elaborated [101]. Recent studies further support the view
that phosphorylation occurs much more often in IDPs
and IDRs as compared to structured proteins and regions
[102,103]. A predictive tool similar to DISPHOS is also
available for protein methylation [104]. These tools can
be utilized to evaluate the abundance of PTMs in the dis-
ease-related unfoldome.
Establishing and analyzing the disease-related unfoldomes
Three approaches were elaborated to estimate the abun-
dance of IDPs in various pathological conditions. The first
approach is based on the assembly of specific datasets of
proteins associated with a given disease and the computa-
tional analysis of these datasets using a number of disor-
der predictors [9,58,77,105]. In essence, this is an analysis
of individual proteins extended to a set of independent
proteins. A second approach utilized network of genetic
diseases where the related proteins are interlinked within
one disease and between different diseases [106]. A third
approach is based on the evaluation of the association
between a particular protein function (including the dis-
ease-specific functional keywords) with the level of intrin-
sic disorder in a set of proteins known to carry out this
function [48-50]. These three approaches are briefly
described below, whereas the results of their application
are presented in the subsequent section.
Simple dataset analysis
The simplest analysis of the abundance of intrinsic disor-
der in a given disease is based on the two-stage protocol,
where a set of related proteins is first assembled by search-
ing various databases and then the collected group of pro-
teins is analyzed for intrinsic disorder. The depth of this
analysis is based on the breadth of the search for the dis-
ease-related proteins and on the number of different com-
putational tools utilized to find disordered proteins/
regions. For example, a dataset of human cancer-associ-
ated proteins (HCAP) extracted from SWISS-PROT http://
www.expasy.ch/sprot using keywords Anti-oncogene;
Oncogene; Proto-oncogene; tumor in the description field
and "human" in the organism field contained 231 pro-
teins [9]. Whereas 487 proteins associated with cardiovas-
cular disease (CVD) were found in SWISS-PROT using an
exhaustive list of CVD-related keywords: Aneurysm;
Angina Pectoris; Angioneurotic Edema; Aortic Valve Sten-
osis; Arrhythmia; Arrhythmogenic; Arteriosclerosis; Arte-
riovenous Malformations; Atrial Fibrillation; Behcet
Syndrome; Bradycardia; Cardiac Tamponade; Cardiomeg-
aly; Cardiomyopathy; Cardiovascular Disease; Carotid
Stenosis; Cerebral Hemorrhage; Churg-Strauss Syndrome;
Ebstein's Anomaly; Eisenmenger Complex; Embolism;
Cholesterol; Endocarditis; Fibromuscular Dysplasia;
Heart Block; Heart Defects; Heart Disease; Heart Failure;
Heart Valve Diseases; Hematoma; Hippel Lindau Disease;
Hyperemia; Hypertension; Hypertrophy; Hypoplastic Left
Heart Syndrome; Hypotension; Intermittent Claudica-
tion; Klippel-Trenaunay-Weber Syndrome; Lateral Medul-
lary Syndrome; Long QT Syndrome; Microvascular
AnginaOR Mitral Valve Prolapse; Moyamoya Disease;
Mucocutaneous Lymph Node Syndrome; Myocardial Inf-
arction; Myocardial Ischemia; Myocarditis; Pericarditis;
Peripheral Vascular Diseases; Phlebitis; Polyarteritis
Nodosa; Pulmonary Atresia; Raynaud Disease; SneddonBMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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Syndrome; Superior Vena Cava Syndrome; Tachycardia;
Takayasu's Arteritis; Telangiectasia; Telangiectasis; Tem-
poral Arteritis; Tetralogy of Fallot; Thromboangiitis Oblit-
erans; Thrombosis; Tricuspid Atresia; Varicose Veins;
Vascular Disease; Vasculitis; Vasospasm; Ventricular
Fibrillation; Williams Syndrome; Wolff-Parkinson-White
Syndrome; Heart disease; Stroke; Thromb; Cardio-vascu-
lar disease; Blood coagulation; Heart muscle; Cardiovas-
cular disease; Plasma; Vascular disease in the description
field and "human" in the organism field [105]. The intrin-
sic disorder analysis in the assembled datasets of disease-
related proteins includes various computational tools
described in a previous section.
Functional keyword analysis
A computational tool for the evaluation of a correlation
between the functional annotations in the SWISSPROT
database and the predicted intrinsic disorder was elabo-
rated [48-50]. First, functional keywords associated with
20 or more proteins in SWISSPROT were determined and
corresponding protein datasets were assembled. Then, for
each keyword-associated set, a length-matching set of ran-
dom proteins was drawn from the SWISSPROT. Order-
disorder predictions were carried out for the keyword-
associated sets and for the random sets. If a function
described by a given keyword were carried out by a long
region of disordered protein, one would expect the key-
word-associated set to have a greater amount of predicted
disorder compared to the random set. The keyword-asso-
ciated set would have less prediction of disorder com-
pared to the random set if the keyword-associated
function were carried out by structured protein. Given the
two sets of predictions for the pairs of sets, it is possible to
calculate the p-values, where a p-value > 0.95 suggests a
disorder-associated function, a p-value < 0.05 suggests an
order-associated function, and intermediate p-values are
ambiguous [48-50].
Genetic diseasenNetwork analysis
To estimate whether human genetic diseases and the cor-
responding disease genes are related to each other at a
higher level of cellular and organism organization, a
bipartite graph was utilized in a dual way: to represent a
network of genetic diseases, the "human disease net-
work", HDN, where two diseases are directly linked if
there is a gene that is directly related to both of them, and
a network of disease genes, the "disease gene network",
DGN, where two genes are directly linked if there is a dis-
ease to which they are both directly related [107]. This
framework, called the human diseasome, systematically
linked the human disease phenome (which includes all
the human genetic diseases) with the human disease
genome (which contains all the disease-related genes).
This diseasome opened a new avenue for the analysis and
understanding of human genetic diseases, moving from
single gene-single disease viewpoint to a framework-
based approach [107].
Using this approach various diseases were classified into
20 types, some diseases were unclassified, and several dis-
eases were annotated as belonging to multiple classes.
Similarly, genes were clustered into classes via their asso-
ciations with specific diseases [107]. The analysis of these
networks revealed that of 1,284 genetic diseases, 867 had
at least one link to other diseases, and 516 diseases
formed a giant component, suggesting that the genetic ori-
gins of most diseases, to some extent, were shared with
other diseases. Similalrly, in the DGN, 1,377 of 1,777 dis-
ease genes were shown to be connected to other disease
genes, and 903 genes belonged to a giant cluster [107].
The vast majority of genes associated with genetic diseases
was non-essential and showed no tendency to encode hub
proteins. In fact, many of the disease-related genes were
shown to be localized in the functional periphery of the
network [107]. The large-scale analysis of the abundance
of intrinsic disorder in transcripts of the various disease-
related genes was performed using a set of computational
tools described in a previous section [106]. The results of
this analysis suggest that IDPs are broadly involved in
human diseases (see below).
IDPs in cancer, CVD, neurodegenerative diseases and 
diabetes
For the first time, the dataset analysis approach was used
in 2002 [9], when significant fractions of cancer-associ-
ated and cell-signaling proteins were found to contain
predicted IDRs of 30 residues or longer (see Figure 4). This
was in a sharp contrast to a set of structured (ordered) pro-
teins with well-defined 3-D structures, which was shown
to contain only 13% of the proteins with predicted IDRs
≥ 30 residues. Following a similar analytical model, a
dataset of 487 proteins related to cardiovascular disease
(CVD) was collected and analyzed [105]. On average,
CVD-related proteins were found to be highly disordered.
They were depleted in major order-promoting residues
(Trp, Phe, Tyr, Ile, and Val) and enriched in some disor-
der-promoting residues (Arg, Gln, Ser, Pro, and Glu).
High level of intrinsic disorder and a substantial number
of potential interaction sites were also found using a set of
computational tools. The percentage of proteins with 30
or more consecutive disordered residues was ~60% for
CVD-associated proteins (see Figure 4). Many proteins
were predicted to be wholly disordered, with 101 proteins
from the CVD dataset predicted to have a total of almost
200 specific disorder-based binding motifs (thus about 2
binding sites per protein). These binding sites are called α-
helical molecular recognition features, α-MoRFs, and
have been well studied from protein complexes taken
from PDB [105]. All of this clearly suggested that IDPs
might play key roles in CVD.BMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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In addition to being abundant in cancer- and CVD-related
proteins, intrinsic disorder was commonly found in such
maladies as neurodegenerative diseases and diabetes. Fig-
ure 4 represents this as the percentages of proteins with ≥
30 consecutive residues predicted to be disordered in
datasets of proteins associated with all four diseases. This
figure shows that intrinsic disorder is highly prevalent in
proteins associated with all of the studied diseases, being
comparable with that of signaling proteins and signifi-
cantly exceeding the levels of intrinsic disorder in eukary-
otic and in non-homologous, structured proteins [58].
Functional anthology of intrinsic disorder and human 
diseases
The application of the functional keyword analysis tool
revealed that out of 710 SWISSPROT keywords each being
assigned to at least 20 proteins, 310 had p-values < 0.05,
suggesting order-associated functions, 238 had p-values >
0.95, suggesting disorder-associated functions, and the
remainder, 162, gave intermediate p-values, yielding
ambiguity in the likely function-structure associations
[48-50].
When the functional keywords were partitioned into
eleven functional categories (Biological processes, cellular
components, developmental stage, etc.) order-associated
keywords were found for seven of the categories, but dis-
order-associated keywords were found for all eleven cate-
gories [48]. Figure 5 represents the results of this analysis
and show that many diseases were strongly correlated
with proteins predicted to be disordered. Contrary to this,
we did not find disease-associated proteins to be strongly
correlated with absence of disorder [50]. Among disease-
related Swiss-Prot keywords strongly associated with
intrinsic disorder were oncoproteins, malaria, trypano-
somiasis, human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS), deafness,
obesity, cardiovascular disease, diabetes mellitus, albi-
nism, and prion [50]. In agreement with this bioinformat-
ics analysis, we were able to find at least one illustrative,
experimentally validated example of functional disorder
or order for the vast majority of functional keywords
related to diseases [50].
Intrinsic disorder in proteins from the genetic disease 
network
The dual Human Disease Network/Disease Gene Network
(HDN/DGN) consists of two types of nodes that represent
human genes (1,777) and diseases (1,284), and links that
connect diseases with related genes [107]. A set of disease
genes from DGN with human genes with known protein
sequences was used to collect protein sequences for all
human genes from NCBI Gene database [106]. All model
proteins obtained solely with automated genome annota-
tion processing were excluded from the consideration.
After this exclusion, the diseasome included 1,751 human
disease related genes. The transcripts of the genetic dis-
Functional anthology of IDPs Figure 5
Functional anthology of IDPs. More than 200,000 pro-
teins and 710 SWISSPROT functional keywords each associ-
ated with at least 20 different proteins were analyzed [48-
50]. Based on the bioinformatics analysis, 238 keywords 
were associated with the predicted intrinsic disorder. These 
keywords covered various functions and included almost all 
disease-related keywords. This is in a strict contrast to 302 
keywords which were associated with the predicted order. 
Functionally, the vast majority of these keywords were vari-
ous "ases". They contained almost no disease-related key-
words.
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Abundance of intrinsic disorder in disease-associated pro- teins Figure 4
Abundance of intrinsic disorder in disease-associated 
proteins. Percentages of disease associated proteins with ≥ 
30 to ≥ 100 consecutive residues predicted to be disordered. 
The error bars represent 95% confidence intervals and were 
calculated using 1,000 bootstrap re-sampling. Corresponding 
data for signaling and ordered proteins are shown for the 
comparison. Analyzed sets of disease-related proteins 
included 1786, 487, 689, and 285 proteins for cancer, CVD, 
neurodegenerative disease and diabetes, respectively.
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ease-associated genes were compared with proteins
encoded by 16,358 other human genes with known pro-
tein sequences [106].
The abundance of intrinsic disorder in these diseasome
network proteins was evaluated by means of several pre-
diction algorithms, including PONDR® VSL2, CDF-analy-
sis, CH-plot [106]. The functional repertoires of these
proteins were analyzed based on prior studies relating dis-
order to function [48-50]. These analyses uncovered an
unfoldome associated with human genetic diseases and
revealed several interesting peculiarities [106]:
(i) Intrinsic disorder is common in proteins associated
with many human genetic diseases;
(ii) Different disease classes vary significantly in the
IDP contents of their associated proteins;
(iii) Molecular recognition features, which are rela-
tively short loosely structured protein regions within
mostly disordered sequences and which gain structure
upon binding to partners, are common in the diseas-
ome, and their abundance correlates with the intrinsic
disorder level;
(iv) Some disease classes have a significantly higher
fraction of genes affected by alternative splicing, and
the alternatively spliced regions in the corresponding
proteins are predicted to be highly disordered and in
some disease classes contain a significantly higher
number of MoRFs;
(v) Correlations were found among the various disea-
some graph-related properties and intrinsic disorder.
In agreement with earlier studies, hub proteins were
shown to be more disordered.
Why the unfoldome and why IDPs?
All the data presented above provide evidence that IDPs
are very common in various diseases and therefore com-
prise a disease-related unfoldome. The introduction of the
unfoldome and unfoldomics concepts pave the way for a
better understanding of the molecular aspects of human
diseases, including a better understanding of their patho-
genesis and molecular mechanisms. This concept is also
important for the development of the appropriate strate-
gies dedicated to the targeted analysis of the disease-
related proteins. As many of these proteins are either com-
pletely disordered or contain long disordered regions, it
would be a clear mistake to analyze them using only the
experimental tools developed for the characterization of
structured proteins. The appropriate conformational anal-
yses should utilize the fact that IDPs and IDRs possess a
range of structural properties that are quite different from
those of ordered proteins [6,7,11,12,14,21]. The tech-
niques used for such analysis were described in a recent
review [57]. Some of these techniques are briefly consid-
ered below.
(i) Although X-ray crystallography is traditionally used
to characterize structure of ordered proteins, it repeat-
edly defines missing electron density in many protein
structures, which may correspond to disordered
region(s). The increased flexibility of atoms in the IDR
leads to the non-coherent X-ray scattering, making
them unobserved or at least smearing out their elec-
tron densities. Missing regions of structure can be
structured but wobbly domains rather than disordered
regions, and so further studies on X-ray identified
IDRs using other methods is very important.
(ii) A solution-based counterpart of X-ray crystallogra-
phy is heteronuclear multidimensional NMR. This is
an extremely powerful technique for protein 3D-struc-
ture determination in solution and for the characteri-
zation of protein dynamics. Recent advances in this
technology have allowed the complete assignment of
resonances for several unfolded and partially folded
proteins, as well as for the several IDPs and IDRs.
(iii) Circular dichroism (CD) is another powerful
technique for the evaluation of the overall tertiary
structure of a protein. CD spectra in the near UV
region (250–350 nm) reflect the asymmetry of the
environment of aromatic amino acid residues and,
consequently, are characteristic of protein tertiary
structure. IDPs may be detected by their display of
simplified near-UV CD spectra.
(iv) Decreased content of ordered secondary structure
in IDPs may be detected by several spectroscopic tech-
niques including far-UV CD, optical rotary dispersion
(ORD), Fourier transform infrared spectroscopy
(FTIR), Raman optical activity and deep UV Raman
spectroscopy.
(v) Hydrodynamic parameters obtained from tech-
niques such as gel-filtration, viscometry, small angle
X-ray or neutron scattering (SAXS or SANS, respec-
tively), sedimentation, dynamic and static light scat-
tering may help in determining the degree of a
polypeptide chain compaction.
(vi) Another very important structural parameter is the
degree of globularity, which reflects the presence or
absence of a tightly packed core in a protein molecule.
This information may be extracted from the analysis of
SAXS data in form of a Kratky plot, the shape of which
is sensitive to the conformational state of the scatter-BMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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ing protein molecules. The Kratky plot of a globular
molecule (ordered or molten globular) has a charac-
teristic maximum, which is absent from the Kratky
plot of a coil-like or pre-molten globule-like IDP.
(vii) Different fluorescence characteristics provide a
wealth of knowledge on the intramolecular mobility
and compactness of a protein. This includes FRET,
shape and position of the intrinsic fluorescence spec-
trum, fluorescence anisotropy and lifetime, accessibil-
ity of the chromophore groups to external quenchers,
and steady state and time-resolved parameters of the
fluorescent dyes.
(viii) Increased proteolytic degradation in vitro of IDPs
and IDRs indirectly confirms their increased flexibil-
ity.
(ix) Protein disorder may also be evaluated by immu-
nochemical methods or via the interaction with
molecular chaperones.
(x) Finally, IDPs may be detected by their response to
the environmental changes or via the analysis of pro-
tein conformational stability.
(xi) Aberrant mobility during the SDS-PAGE gel elec-
trophoresis may be suggestive of intrinsic disorder
since disordered proteins usually migrate slower than
their calculated molecular weight.
As discussed above, IDPs and IDRs can be characterized
by a variety of biophysical and biochemical methods. As
a result, a very large number of disease-associated proteins
have been experimentally shown to be IDPs or to contain
IDRs as indicate by the illustrative examples at the begin-
ning of this article. This leads naturally to the following
question: from a biological perspective, why have such
proteins been so heavily linked to human diseases? To
answer this question, some specific features of IDPs that
potentially make them key players in the development of
pathological conditions need to be considered. Many of
these features are linked to the function of IDPs in signal-
ing, regulation and control. The list of these features
includes [24]:
(i) Decoupled specificity and strength of binding lead-
ing to high-specificity-low-affinity interactions;
(ii) Increased speed of interaction due to greater cap-
ture radius and the ability to spatially search interac-
tion space;
(iii) Flexible encounter complexes (less stringent spa-
tial orientation requirements);
(iv) Controlled regulation via high sensitivity to prote-
olytic degradation when in the free state;
(v) Increased interaction (surface) area per residue;
(vi) A one-to-many binding mode and binding pro-
miscuity by which a single IDP/IDR binds to multiple
structurally diverse partners. This is accomplished by
plasticity, by which a given IDR folds into distinctive
conformations to accommodate the diverse binding
sites of its different partners
(vii) A many-to-one binding mode, by which many
different IDPs/IDRs bind to one site on a single
ordered partner. Again this is accomplished by plastic-
ity, by which different IDRs fold into similar confor-
mations that all fit into a single binding site on one
partner.
(viii) Induced folding where an IDR folds as it binds
to a specific partner;
(ix) Low steric restrictions allowing the elongation or
contraction of a given binding area;
(x) Ease of regulation or reorganization of signaling
networks by posttranslational modification;
(xi) Ease of regulation or reorganization of signaling
networks by alternative splicing;
(xii) Overlapping of binding sites due to use of
extended linear conformations for association;
(xiii) High evolutionary rates leading to rapid adapta-
bility and easy modification of signaling networks;
(xiv) Flexibility that allows masking (or not) of inter-
action sites or that allows multiple interactions
between bound partners.
Induced folding, binding promiscuity, and binding plasticity
Protein-protein and protein-nucleic acid interactions are
central to many processes in molecular biology. They
often involve coupled folding and binding of at least one
of the partners [4,6-8,10,13,17,22,108,109]. Among the
list of structural features that make IDPs especially useful
for their signaling and regulation functions include
induced folding, binding promiscuity, and binding plas-
ticity. The p53 protein molecule represents an especially
dramatic example for which intrinsic disorder is heavily
utilized for function via induced folding, binding promis-
cuity (i.e., the ability of a given IDP to bind interact with
several binding partners), and binding plasticity (which is
determined as the ability of a given IDR to gain differentBMC Genomics 2009, 10(Suppl 1):S7 http://www.biomedcentral.com/1471-2164/10/S1/S7
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folds to accommodate diverse binding sites of different
partners). As it has been already mentioned, p53 regulates
expression of over 150 genes and binds to over 100 pro-
teins [51,70,71]. These many interactions represent an
illustrative example of the one-to-many biding mode
[51]. The 3-D structures of several complexes between the
various p53 regions and unique binding partners have
been determined (see Figure 3). The interactions with 10
of these partners are mediated by region experimentally
characterized as IDRs. Figure 3 shows that PONDR® VLXT
is able to detect the majority of these binding regions as
short predictions of order within a longer prediction of
disorder. These structures are complexes between p53
and: cyclin A, sirtuin, CBP, S100ββ, set9, tGcn5, Rpa70,
Mdm2, Tfb1, and itself. The remaining 4 interactions are
mediated by the structured DBD, between p53 and: DNA,
53BP1, sv40 Large T antigen, and 53BP2 [51].
Of special interest is the C-terminal regulatory domain,
which is involved in the formation of multiple complexes.
Figure 3 shows that a single IDR of p53 derived from the
C-terminal regulatory domain (residues 374–388) was
observed to form all three major secondary structure types
in the bound state: a helix when associating with S100ββ,
a sheet with sirtuin, an irregular structure with CBP, and
an irregular structure with a completely different trajec-
tory with cyclin A2. The set of residues involved in these
interactions exhibit a very high extent of overlap along the
sequence [51]. Based on the fact that the secondary struc-
tures adopted by this IDR in different complexes were very
distinct, it seemed reasonable to expect that p53 utilizes
different residues for the interactions with these four dif-
ferent binding partners. This hypothesis is supported via
the quantification of the buried surface area for each resi-
due in each interaction by calculating their ΔASA [51]. In
fact, the ΔASA-based binding profiles for the single IDR of
p53 bound to four different partners were completely dif-
ferent, indicating that the same residues were used to dif-
ferent extents in the four interfaces, suggesting that the
same IDR sequence is "read" by the different partners in
entirely different ways [51].
This intriguing p53 example demonstrates the roles of
IDRs in determining multiple specificities associated with
the one-to-many binding mode, where remarkable con-
formational changes enable very distinct surfaces to be
formed for binding to different partners. The mentioned
interactions of the C-terminal regulatory domain of p53
with various binding partners are used for the activation
or inhibition of its primary role as a transcription regula-
tor. Therefore, it is possible that the disordered binding
regions may play a passive regulatory role by providing a
specific binding site, where IDRs serve as the identifica-
tion sites of the protein to be regulated [13,51].
Because p53 is so heavily studied, we have learned about
the use of IDPs and IDRs for its functions, especially as
providing sites for protein-protein interactions, before we
have gained such knowledge for other signaling proteins.
However, sites of protein-protein interactions that are
located within IDPs and IDRs and that are very similar to
those observed for p53 are predicted to be extremely com-
mon in the proteins of mammalian proteomes [91]. Thus,
what we have presented above for p53 likely provides a
blueprint for the use of IDPs and IDRs for a very large
number of proteins in the cell.
Overall, there are intriguing interconnections among
intrinsic disorder, cell signaling and human diseases, sug-
gesting that protein conformational diseases may result
not only from protein misfolding, but also from misiden-
tification and missignaling.
Concluding remarks
Intrinsic disorder is highly abundant among proteins
associated with various human diseases. This conclusion
is based on the detailed analysis of several well-character-
ized disease-related IDPs and on the results of the exten-
sive bioinformatics studies. As the number of disease-
related IDPs is very large and as many of these proteins are
interlinked, the concepts of the disease-related unfoldome
and unfoldomics were introduced. Here, the disease-
related unfoldome is attributed to a significant part of
human proteome, which includes malady-associated
IDPs, their functions, structures, interactions, evolution,
etc. We believe that the unfoldomics concept helps lead to
better understanding of various human diseases, their
pathogenesis and molecular mechanisms. This concept
might also help in the development of specialized strate-
gies for the targeted analysis of functional and structural
properties of disease-related proteins. The high degree of
association between intrinsic disorder and many proteins
implicated in various maladies is due to structural and
functional peculiarities of IDPs and IDRs, which are typi-
cally involved in cellular regulation, recognition and sig-
nal transduction. One of the promising future
developments in the field of the disease-related
unfoldome and unfoldomics is the evaluation of IDP/IDR
abundance in the framework of disease ontology. How-
ever, since the corresponding resources are not ready yet,
such an analysis might be difficult at the current point.
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